)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Initiator Pharma
Initiator Pharma (INIT) investor relations material
Initiator Pharma Investing in Life Science 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investing in Life Science 2026 summary22 Sep, 2026
Strategic leadership and team developments
Recent appointments have strengthened operational and business development capacity, with a focus on women's health.
Board member Kristina Östby Lloyd brings senior international pharma experience, reinforcing commitment to women's health.
Scientific innovation and clinical pipeline
Pudafensine, a novel monoamine modulator, targets dopamine reuptake for precise efficacy and superior safety.
Clinical programs include erectile dysfunction (ED) and vulvodynia, with strong phase II-B data in ED and ongoing phase II-A in vulvodynia.
Pudafensine addresses non-responders to standard ED treatments, representing about 35% of patients.
Preclinical and clinical evidence supports central pain relief in vulvodynia, a chronic pain condition affecting 8–10% of women.
Market opportunity and business development
Vulvodynia represents a large, underserved market with no approved treatments and over 30 million affected women in Europe and the US.
Conservative estimates forecast peak sales over $4 billion for pudafensine in vulvodynia.
Ongoing business development includes advancing partner discussions for vulvodynia and ED programs, leveraging strong data and IP.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Initiator Pharma
- Full strategic focus on pudafensine, with Phase IIa vulvodynia trial on track and robust IP secured.INIT
Q2 2026 - Pudafensine prioritized after IP2018 discontinuation, with robust clinical and financial positioning.INITQ1 2026
- Pudafensine targets major unmet needs in ED and vulvodynia, with pivotal data due in late 2024.INITDNB Carnegie Healthcare Seminar 2026
- Pudafensine targets major unmet needs in ED and vulvodynia, with pivotal data expected by 2026.INITStora Aktiedagarna 2026
- Phase IIa vulvodynia trial underway, strong IP, and solid financing position for 2026.INITQ4 2025
- Advanced clinical pipeline and secured major financing, with focus on vulvodynia and ED markets.INITQ3 2025
- First-in-class therapy for vulvodynia enters pivotal trial, targeting a multibillion-euro market.INITLife Science Summit 2025
- Pudafensine advances to Phase II for vulvodynia, targeting major unmet needs in women's health.INITInvesting in Life Science 2025
- Pudafensine advanced to Phase IIa for vulvodynia, with strong funding and reduced Q2 losses.INITQ2 2025
Next Initiator Pharma earnings date
Q3 202620 Nov, 2026
Initiator Pharma
Next Initiator Pharma earnings date
Q3 202620 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage